Design Therapeutics (DSGN) Competitors

CureVac (NASDAQ:CVAC) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership, community ranking and profitability.

Is CVAC or DSGN more profitable?

CureVac has a net margin of 20.72% compared to Design Therapeutics' net margin of 0.00%. CureVac's return on equity of 21.98% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	20.72%	21.98%	15.72%
Design Therapeutics	N/A	-18.01%	-17.38%

Does the media prefer CVAC or DSGN?

In the previous week, Design Therapeutics had 1 more articles in the media than CureVac. MarketBeat recorded 5 mentions for Design Therapeutics and 4 mentions for CureVac. Design Therapeutics' average media sentiment score of 0.37 beat CureVac's score of 0.08 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CureVac	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Design Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, CVAC or DSGN?

CureVac has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.

Which has higher valuation and earnings, CVAC or DSGN?

Design Therapeutics has lower revenue, but higher earnings than CureVac. Design Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$535.18M	1.70	-$281.58M	$0.82	4.96
Design Therapeutics	N/A	N/A	-$66.86M	-$0.99	-3.57

Do analysts recommend CVAC or DSGN?

CureVac currently has a consensus target price of $14.00, indicating a potential upside of 244.40%. Design Therapeutics has a consensus target price of $4.00, indicating a potential upside of 13.31%. Given CureVac's stronger consensus rating and higher probable upside, equities research analysts clearly believe CureVac is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Design Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the MarketBeat Community favor CVAC or DSGN?

CureVac received 17 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 56.25% of users gave CureVac an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote.

Company	Underperform	Outperform
CureVac	Outperform Votes 27 56.25%	Underperform Votes 21 43.75%
Design Therapeutics	Outperform Votes 10 33.33%	Underperform Votes 20 66.67%

Do insiders and institutionals hold more shares of CVAC or DSGN?

17.3% of CureVac shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 31.2% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

CureVac beats Design Therapeutics on 12 of the 17 factors compared between the two stocks.